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Abstract Visfatin with the official gene name pre-B cell
colony-enhancing factor 1 (PBEF) and the protein name
nicotinamide phosphoribosyltransferase (NAMPT) is a
recently discovered adipocyte-secreted protein that was
shown by some to be associated with visceral fat and
insulin resistance. To explore the link between PBEF/
NAMPT/visfatin and lipid metabolism, we analyzed the
relation of its plasma level with several parameters of
adiposity, insulin resistance and the circulating blood lipid
profile in a group of general population (n=40) and a group
of subjects who are genetically predisposed to insulin
resistance and hyperlipidemia (n=35). In both groups and
pooled cohort, PBEF/NAMPT/visfatin lacked association
with whole body adiposity, but correlated positively with
HDL-cholesterol and negatively with triglycerides. The
data suggested a negative correlation of the PBEF level
with visceral fat and insulin resistance. But this negative
correlation completely disappeared after adjustment for lipid
profile. We concluded that circulating PBEF/NAMPT/
visfatin level is an indicator of beneficial lipid profile in
non-diabetic Caucasian subjects. The relation to lipid
metabolism does not depend on visceral obesity and insulin
resistance, but may be linked to its enzymatic function in
NAD metabolism.
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Abbreviations
BMI body mass index
FCHL familial combined hyperlipidemia
HOMA homeostasis model assessment
NAD nicotinamide adenine dinucleotide
NAMPT nicotinamide phosphoribosyltransferase
PBEF pre-B cell colony-enhancing factor 1
Introduction
Visfatin is a recently discovered adipocyte-secreted protein
that was shown to be associated with visceral fat in humans
and rodents [1]. Visfatin was also shown to mimic the effect
of insulin with the same efficacy in rodent cells in vitro and
in mouse models [1]. However, subsequent studies in
human subjects reported conflicting results with regard to
its relation with adiposity [2–4], subcutaneous or visceral
fat [2, 3], and insulin resistance [3–5], suggesting that the
role of this protein in the development of obesity and
insulin resistance remains unclear.
Visfatin is a rediscovery of the cytokine-like protein pre-B
cell colony-enhancing factor 1 (PBEF1) [6]. It was also
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identified as cytosolic nicotinamide phosphoribosyltransfer-
ase (NAMPT), demonstrated by in vitro, in vivo, and
structural studies [7–9]. This enzyme is involved in
nicotinamide adenine dinucleotide (NAD) biosynthesis [8].
Visceral fat, together with insulin resistance, contributes to
an abnormal lipid metabolism [10]. In view of the possible
association of PBEF with adipose tissue and insulin
resistance, we wondered if the circulating level of PBEF
could be related to lipid metabolism in humans. We analyzed
the relation of plasma PBEF with several parameters of
adiposity, insulin resistance, and with the plasma lipid profile
in Caucasian subjects from the general population. In
addition, we used another Caucasian group of subjects with
predisposed lipid metabolism disorder to strengthen the
findings. In this case, familial combined hyperlipidemia
(FCHL) family relatives were chosen because FCHL is a
disorder of lipoprotein metabolism in the presence of insulin
resistance, and it is known that the accumulation of
abdominal fat, especially visceral fat, is highly prevalent in
FCHL families [11]. To avoid the influence of type 2 diabetes
[4, 5], only non-diabetic subjects were enrolled in this study.
Materials and methods
Subjects
The general population group is composed of 40 Caucasian
non-diabetic genetically independent males and females.
They were extracted from the spouses databank of FCHL
families [12] to constitute a broad range of body mass index
(BMI). Thirty-five non-diabetic age-matched and gender-
matched Caucasian FCHL family members were recruited
for the FCHL relatives group. They were selected to cover a
broad range of BMI as well and were drawn evenly from 16
unrelated families to avoid profound genetic influences
from a single family. All subjects visited the Maastricht
research clinic between 2003 and 2005 where the plasma
samples were collected. The study protocol has been
described in detail elsewhere [12]. Any lipid-lowering
medication had been withdrawn during the last 2 weeks
before blood sampling. The Medical Ethical Committee of
University Hospital Maastricht approved the study, and all
subjects gave written informed consent.
Anthropometrical measurements
Body weight, height, and body mass index (BMI) were
measured in fasting state as described previously [11]. The
skinfold thickness of biceps, triceps, subscapular and
suprailiac regions was measured, and percentage body fat
was derived from the sum of the four skinfold measure-
ments using the method of Durnin and Womersley [13].
The size of subcutaneous adipose tissue and visceral
adipose tissue were measured with an ultrasound method as
described elsewhere [12], which has been validated [14].
Biochemical measurements
Fasting venous blood samples were collected in pre-cooled
EDTA vacutainer tubes and immediately processed. EDTA–
plasma aliquots were stored at −80°C until analysis.
Triglycerides, total cholesterol, HDL-cholesterol and LDL-
cholesterol, ApoB lipoprotein, glucose, and insulin were
measured as described previously [11]. The homeostasis
model assessment (HOMA) score was calculated as an
index of insulin resistance [15]. PBEF was measured using
a commercial enzyme immunoassay kit (Phoenix, Belmont,
NY, USA) according to the manufacturer’s instruction. In
this assay, the blood samples were threefold diluted.
Samples were measured in duplicate and the average was
used in the data analysis. The intra-assay and inter-assay
coefficients of variation were 12% and 17%, respectively.
The detection limit was 1 ng/ml.
Statistic analysis
All analyses were performed with SPSS 12.0 (SPSS, Chicago,
IL, USA). All values are expressed as the mean±standard
deviation (SD). Variables significantly deviating from normal
distribution were logarithmically transformed. For comparing
the males and females inside the group, independent-samples
t-test was used. For comparing the mean of the groups, age-
adjusted and gender-adjusted t-test was used. The associa-
tions among the parameters were assessed by age-adjusted
and gender- adjusted partial correlation analysis within the
groups, and further group identity-adjusted analysis in the
pooled subjects. Subsequently, for parameters of a correla-
tion with PBEF at a significance level <0.10 in the pooled
cohort, multiple linear regression analysis was performed to
assess the independent relation. Statistical calculations were
performed two-tailed and a p value <0.05 was considered
statistically significant.
Results
Characteristics of the subjects
Both individually and combined, the general population
and FCHL relatives groups comprised a broad range in
adiposity: BMI was 20.0–35.6 for the former and 21.0–40.0
for the latter. The same held true for insulin resistance. The
HOMA score ranged from 0.43 to 4.16 and from 0.61 to
7.68, respectively. By definition, FCHL relatives had higher
972 Pflugers Arch - Eur J Physiol (2007) 454:971–976
plasma concentrations of triglycerides and cholesterol. As
expected, additional differences were seen in adiposity,
especially intra-abdominal (visceral) adiposity, and insulin
resistance. However, the average plasma PBEF levels did
not differ between the two groups (Table 1). In both groups,
there was some difference between male and female
subjects on the parameters of adiposity and lipid profile,
but no difference with respect to the plasma PBEF level.
The relation between plasma PBEF level, adiposity,
insulin resistance, and plasma lipid profile
The correlations after adjusting for age and gender between
BMI or visceral fat and HOMA score or lipid profile were
as expected (Table 2). Although there was no essential
difference between the two groups, the relation between
visceral fat and HDL-cholesterol was weaker in the group
of FCHL relatives, which could be caused by the
heterogeneity of predisposing genetic factors that specifically
affect the HDL-cholesterol level. Additional relations between
metabolic parameters were also as anticipated; both in the
general population and FCHL relatives groups. BMI and
visceral adipose size were highly correlated (r=0.622, p<
0.001 and r=0.577, p<0.001, respectively), as were total
plasma triglycerides and HOMA score (r=0.486, p=0.002
and r=0.441, p=0.010, respectively), while a strong negative
association was observed between triglycerides and HDL-
cholesterol (r=−0.404, p=0.010 and r=−0.602, p<0.001,
respectively). These results confirm that, despite a relatively
small sample size, all known relations behaved as expected.
In the general population group, plasma PBEF level was
negatively correlated with visceral adipose depot size, but
not associated with other adiposity indicators, including
BMI, body fat percentage, and size of subcutaneous
adipose depots. The PBEF in this group was negatively,
but not significantly, correlated with the HOMA score as a
measure for insulin resistance. However, PBEF correlated
positively with HDL-cholesterol and negatively with
triglycerides (Table 3). In the FCHL relatives group, plasma
PBEF level showed similar correlations with HDL-cholesterol
and triglycerides, and was not correlated with any of the other
parameters (Table 3 and Fig. 1).
To assess the independent relation, we performed
multiple linear regression. Because the correlations were
similar in both groups, we pooled the data with adjustment
for group identity to increase the power. In the pooled data,
HDL-cholesterol, log10triglycerides, log10HOMA, and
log10visceral fat size were significantly correlated with
PBEF level. When HDL-cholesterol, log10triglycerides,
log10HOMA, and log10visceral fat size together with body
fat percentage, age, gender, and group identity were entered
as independent variables into a model with log10PBEF as
the dependent variable, multiple linear regression showed
that HDL-cholesterol, but not body fat percentage, visceral
fat size or HOMA score, was an independent predictor of
plasma PBEF. Age and gender did not show significant
Table 1 Anthropometrical and biochemical characteristics of the subjects
General population (n=40) FCHL relatives (n=35) pa
Male Female pb Male Female pb
Number 21 19 15 20 n.s.c
Age (years) 50.6±11.2 47.4±7.3 n.s. 49.8±10.2 53.8±7.3 n.s. n.s.d
BMI (kg/m2) 27.6±4.0 26.0±4.4 n.s. 28.0±4.5 31.6±4.5 0.027 0.007
Body fat percentage 28.6±6.1 37.6±5.9 <0.001 28.9±4.3 42.2±3.4 <0.001 n.s.
Subcutaneous fat (cm) 2.28±1.06 3.33±1.18 0.005 2.31±0.90 3.79±1.10 <0.001 n.s.
Visceral fat (cm)e 9.00±2.71 6.36±1.47 0.001 9.90±3.43 10.12±2.91 n.s. 0.001
HOMA scoree 1.37±0.93 1.44±0.87 n.s. 2.51±1.76 2.99±1.28 n.s. <0.001
Total cholesterol (mmol/l)e 5.19±0.80 5.30±0.94 n.s. 6.26±1.68 6.50±1.45 n.s. 0.001
Triglycerides (mmol/l)e 1.59±0.83 1.24±0.51 n.s. 2.61±1.68 2.76±1.64 n.s. <0.001
HDL-cholesterol (mmol/l) 0.92±0.20 1.04±0.22 n.s. 0.76±0.19 0.92±0.21 0.032 0.007
LDL-cholesterol (mmol/l)e 3.56±0.77 3.71±0.87 n.s. 4.32±1.57 4.36±1.30 n.s. 0.029
ApoB (g/l)e 0.96±0.18 1.08±0.29 n.s. 1.18±0.29 1.31±0.25 n.s. 0.001
PBEF (μg/ml)e 39.3±12.8 35.8±11.0 n.s. 40.9±13.7 39.7±13.5 n.s. n.s.
Data are expressed as the mean±SD.
n.s.: not significant
a Age-adjusted and gender-adjusted t-test for the difference between the means of the groups.
b Independent-samples t-test for the difference between the means of the males and females inside the group.
c Only age-adjusted.
d Only gender-adjusted.
e Log transformed data were used in t-test.
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influence on the PBEF. However, the group identity made
significant contribution to the model. This model could
explain approximately 30% of the variance in plasma PBEF
level (Table 4).
Discussion
The aim of the present study was to test the link between
PBEF and lipid metabolism. Our results showed that in
non-diabetic human subjects, plasma PBEF level is corre-
lated to a high HDL-cholesterol/low triglyceride plasma
lipid profile. This relation is conserved in subjects predis-
posed to a disorder of lipoprotein metabolism in the
presence of insulin resistance (FCHL relatives). Although
the size of the study cohorts was limited, the repeated
finding corroborates that circulating PBEF has a relation
with lipid metabolism in humans.
The significant associations of circulating PBEF with
HDL-cholesterol and triglycerides in Caucasians have not
been reported before. Very recently, Smith et al. reported
that non-fasting serum PBEF level correlated positively to
HDL-cholesterol and apolipoproptein A1 in Asian Indians;
but this was not replicated in Caucasians [16]. The
difference between their result on Caucasians and ours is
probably caused by the non-fasting samples used in their
study while our results were obtained from fasting state.
The use of fasting samples additionally allowed us to
detect the correlation with plasma triglycerides. Together,
it indicates that the relation between circulating PBEF and
HDL-cholesterol may be universal: in Asians and in
Caucasians, in the general population, and in the subjects
with genetic predisposition for dyslipidemia. In the study
of Pagano et al. [3], the relation between PBEF and lipid
profile was not analyzed. However, the Caucasian obese
group that had a significantly lower level of HDL-
cholesterol and higher level of triglycerides also showed
a significantly lower level of plasma PBEF compared to
the lean group. This supports our findings.
The relation between PBEF and lipid profile may be
explained in the light of the cytosolic function of PBEF as a
nicotinamide phosphoribosyltransferase (NAMPT). NAD
has been established as a molecule, similar to ATP, that
plays an important dual role as energy and signal transducer
[17]. This enzyme salvages the nicotinamide that is formed
during NAD metabolism to replenish the cellular NAD
Table 2 Correlation (age-ad-
justed and gender-adjusted)
between adiposity and the
measures of insulin resistance
and lipid metabolism
The bold p values are significant.
a Log transformed data.
General population FCHL relatives
BMI Visceral fat sizea BMI Visceral fat sizea
HOMA scorea r 0.514 0.505 0.449 0.545
p 0.001 0.001 0.009 0.001
Total triglyceridesa r 0.391 0.655 0.063 0.378
p 0.015 <0.001 0.726 0.030
HDL-cholesterol r −0.260 −0.339 −0.299 −0.183
p 0.115 0.038 0.091 0.307
Table 3 The correlation coefficients (age-adjusted and gender-adjusted) between plasma PBEF level and other parameters
General population FCHL relatives Pooleda
r p r p r p
Age 0.009b 0.957b 0.211b 0.230b 0.103b 0.388b
BMI −0.033 0.846 −0.298 0.092 −0.158 0.369
Body fat percentage −0.209 0.207 −0.202 0.259 −0.207 0.084
Subcutaneous fat size −0.040 0.811 0.230 0.198 0.049 0.683
Visceral fat sizec −0.345 0.034 −0.256 0.150 −0.269 0.023
HOMA scorec −0.278 0.092 −0.230 0.198 −0.245 0.039
Total cholesterolc −0.169 0.309 −0.130 0.471 −0.144 0.229
Triglyceridesc −0.402 0.012 −0.465 0.006 −0.408 <0.001
HDL-cholesterol 0.469 0.003 0.403 0.020 0.439 <0.001
LDL-cholesterolc −0.138 0.408 0.023 0.900 −0.073 0.547
ApoBc −0.293 0.074 −0.046 0.799 −0.182 0.129
The bold p values are significant.
a Adjusted for group identity in pooled groups.
b Only adjusted for gender.
c Log transformed data.
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level. This pathway may have beneficial impact on aging
and longevity [9, 18]. It is interesting to note that it has
been observed that oral administration of nicotinamide
significantly increased cellular NAD level and serum HDL-
cholesterol level in hemodialysis patients. The change of
HDL-cholesterol correlated significantly with the change of
NAD concentration in total blood cells [19]. Another NAD
biosynthesis substrate, nicotinic acid, has been reported as
the most potent agent for raising HDL-cholesterol [20].
Altogether, these observations strongly suggest that main-
tenance of the beneficial high HDL-cholesterol/low plasma
triglycerides phenotype [21] may be associated with NAD
metabolism. Our finding on the association of circulating
PBEF with the plasma lipid profile implies that PBEF may
serve as the link between those two processes. Presently, it
is unclear how the cytosolic function of this protein is
reflected in its extracellular level. It has been suggested that
the release of PBEF into the culture medium in in vitro studies
is most likely due to cell leakage [8]. But the significant
amount of the circulating level suggests that extracellular
PBEF is not merely derived from cell leakage. Therefore, the
source of circulating PBEF still needs to be defined.
Remarkably, the group identity (i.e. general population
or FCHL relatives) was significantly associated with
plasma PBEF level in the multiple linear regression model,
despite the comparable plasma levels of PBEF in the
general population and FCHL relatives. This suggests that
the genetic predisposition for FCHL may influence the
circulating level of PBEF. The relation between FCHL and
PBEF may be evaluated in a larger FCHL population
including other un-identified factors beyond our model in
future investigations, which is beyond the scope of our
present study.
Visceral adiposity and insulin resistance are not the
reason behind the relation between PBEF and lipid
metabolism. We could not find the associations of circulat-
ing PBEF with general adiposity and insulin resistance in
either of the present groups. This could be due to the
limited cohort size. However, this also implies that the link
between PBEF and lipid metabolism may be related more
to the real role of PBEF. Our result on the negative
correlation between the circulating PBEF and visceral fat in
the general population group confirmed the previous study
in healthy subjects [3]. Our pooled data suggested a
negative correlation of the PBEF level with visceral fat
and insulin resistance, but they completely disappeared
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Fig. 1 Scatter plot for plasma PBEF level and lipid profile (a HDL-
cholesterol, b triglycerides). Filled dots and regression line: the
general population group. Empty dots and dashed regression line: the
FCHL relatives group
Table 4 Multiple linear re-
gression model-corrected cor-
relation between plasma PBEF
level and other parameters
The bold p values are significant.
a General population=0 and
FCHL relatives=1 in the dum-
my variable of group identity.
b Log transformed data.
Model R2 Model p Standardized coefficient p
0.286 0.003 Group identitya 0.374 0.005
Gender −0.126 0.521
Age 0.190 0.116
Body fat percentage −0.169 0.408
Visceral fat sizeb −0.045 0.804
HOMA scoreb 0.026 0.871
Triglyceridesb −0.265 0.115
HDL-cholesterol 0.337 0.013
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after adjustment for lipid profile. Although PBEF has been
regarded as an adipose tissue-related hormone, studies
show that PBEF is ubiquitously expressed in the body.
Among different human tissues, the maximum gene expres-
sion was found in the liver and peripheral blood leukocytes [6,
22]. A large-scale analysis of the human transcriptome
indicated that the PBEF gene is highly expressed in whole
blood, over 100 times of the median abundance, while the
expression in adipocytes is just about 2 times of the median
abundance (GEO series GSE1133) [23].
A recent study has shown lack of association between
circulating PBEF level and glucose metabolism/insulin
resistance in healthy lean and obese subjects [3]. In humans,
the normal fasting PBEF level is 10–40 ng/ml [1–5], which
equals 180–700 pmol/l for this 55 kDa protein, 3.6–14 times
the concentration of the normal fasting insulin level
(50 pmol/l). If PBEF could act with the same efficacy as
insulin [1], it should contribute importantly to the regulation
of glucose metabolism. Therefore, it suggests that the
circulating PBEF is not likely to play a major role in the
glucose metabolism in humans.
In conclusion, the significant associations, positively
with HDL-cholesterol and negatively with triglycerides,
suggest that circulating PBEF is an indicator of beneficial
lipid metabolism in non-diabetic Caucasian subjects,
possibly linked to NAD metabolism. The relation with
lipid metabolism does not depend on visceral obesity and
insulin resistance. Further mechanistic studies in this
direction may help to understand the physiological role of
circulating PBEF.
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